News and analysis on disease research and diagnostics.
The health system said that the program is encouraging patient compliance and increasing revenues and savings.
Deleterious NOTCH mutations may predict more favorable immune checkpoint responses in lung cancer patients without EGFR or ALK mutations.
Women with breast cancer from Peru, Mexico, or Colombia who had greater Indigenous American ancestry were more likely to have HER2-positive tumors.
Following a positive interim analysis of the Phase III OVAL trial, Japan-based NanoCarrier plans to open trial sites for VBL Therapeutics' VB-111.
The large BRCA1 deletion, which was not captured by initial genetic testing, might be the reason for the patient's exceptional response to a PARP inhibitor.
